Approximately 81% of oncologists said patients should consent to artificial intelligence use for cancer treatment decisions, a recent survey found.
The survey, published March 28 in JAMA Network Open, surveyed 204 oncologists between Nov. 15, 2022, and July 31, 2023.
Researchers found that 46.6% of oncologists said they received some education on AI use in healthcare, and 45.3% reported familiarity with clinical decision models. Of participants, 84.8% said AI-based clinical decision models needed to be explainable by oncologists but did not need to be explained to patients. However, 81.4% said patients should consent to the use of AI models to support treatment decisions.
Oncologists also said AI developers were responsible for medico-legal problems associated with AI use. About 76% of oncologists said they should protect patients from biased AI tools; however, only 27.9% said they were confident in their ability to identify poorly representative AI models.